Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 76 Neoplasms 28 Lung Neoplasms 24 Neoplasm Metastasis 12 Mesothelioma, Malignant 11 Mesothelioma 10 Colorectal Neoplasms 10 Ovarian Neoplasms 6 Unspecified Adult Solid Tumor, Protocol Specific 5 Small Cell Lung Carcinoma 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Melanoma 5 Head and Neck Neoplasms 5 Breast Neoplasms 5 Adenocarcinoma of Lung 5 Pancreatic Neoplasms 4 Carcinoma 4 Advanced Cancer 4 Squamous Cell Carcinoma of Head and Neck 3 Rectal Neoplasms 3 Meningeal Carcinomatosis 3 Lymphoma, Non-Hodgkin 3 Lymphoma 3 Esophageal Neoplasms 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Advanced Solid Tumors 3 Adenocarcinoma 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2

Interventions

Imatinib Mesylate 2 spartalizumab 1 pembrolizumab 1 nilotinib 1 Thiotepa 1 Radiotherapy 1 Radiosurgery 1 Photochemotherapy 1 Peripheral Blood Stem Cell Transplantation 1 Pemetrexed 1 Panobinostat 1 Nivolumab 1 Melphalan 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Dihematoporphyrin Ether 1 Cyclophosphamide 1 Cetuximab 1 Busulfan 1 Bone Marrow Transplantation 1 Blood Specimen Collection 1 Bacterial Load 1 Amifostine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Chordoma × Pemetrexed × Clear all

NCT03955042 2023-03-07

Pemetrexed for the Treatment of Chordoma

Saint John's Cancer Institute

Phase 1 Completed

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡